+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Walking impairment in patients with multiple sclerosis - a new therapeutic approach and clinical potential of dalfampridine extended release tablets



Walking impairment in patients with multiple sclerosis - a new therapeutic approach and clinical potential of dalfampridine extended release tablets



Degenerative Neurological and Neuromuscular Disease 2: 53-64



Walking impairment is a clinical hallmark of multiple sclerosis (MS) that has been under-recognized as a therapeutic target for pharmacologic intervention. The development and approval of dalfampridine extended release tablets (dalfampridine-ER; known as prolonged-, modified, or sustained-release fampridine outside the USA), 10 mg taken twice daily, to improve walking in patients with MS, fills a previously unmet need. In three randomized, double-blind, placebo-controlled trials, dalfampridine-ER improved walking speed in approximately one-third (37%) of treated patients, and average walking speed on therapy among these responders improved by approximately 25% relative to baseline. Walking-speed improvement among responders was clinically significant, as determined by a statistically significant improvement in the patient-reported 12-item Multiple Sclerosis Walking Scale. Long-term extension studies indicate that responders were able to maintain benefits, compared with nonresponders over prolonged periods of treatment. Dalfampridine-ER was generally well tolerated. Dizziness, insomnia, balance disorder, headache, nausea, urinary tract infection, and asthenia were the most common adverse events. Although the incidence of seizures appeared to be dose related, among patients treated with dalfampridine-ER in the three trials, the rate of seizures was 0.25%. These efficacy and safety data suggest that dalfampridine-ER can be a useful and clinically relevant addition to the pharmacologic armamentarium for the management of MS symptoms and disabilities. Because of its narrow therapeutic index and potential for seizures, it is especially important in the clinical setting to adhere to the dosing recommended in the approved labels.

(PDF emailed within 0-6 h: $19.90)

Accession: 066606960

Download citation: RISBibTeXText

PMID: 30890878

DOI: 10.2147/dnnd.s19839


Related references

Extended-release dalfampridine in the management of multiple-sclerosis-related walking impairment. Therapeutic Advances in Neurological Disorders 5(4): 199-204, 2012

Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis. Neuropsychiatric Disease and Treatment 7: 229-239, 2011

Effects of Dalfampridine Extended-release Tablets on 6-minute Walk Distance in Patients With Multiple Sclerosis: A Post Hoc Analysis of a Double-blind, Placebo-controlled Trial. Clinical Therapeutics 37(12): 2780-2787, 2016

Development of dalfampridine, a novel pharmacologic approach for treating walking impairment in multiple sclerosis. Annals of the New York Academy of Sciences 1329: 33-44, 2015

Pharmacokinetic profile of dalfampridine extended release: clinical relevance in patients with multiple sclerosis. Current Medical Research and Opinion 29(12): 1627-1636, 2014

Prescriber utilization of dalfampridine extended release tablets in multiple sclerosis: a retrospective pharmacy and medical claims analysis. Therapeutics and Clinical Risk Management 11: 1-7, 2015

Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials. Multiple Sclerosis 21(10): 1322-1331, 2016

Quality of Life Among Patients with Multiple Sclerosis Treated with Prolonged-Release Fampridine 10 Mg Tablets for Walking Impairment. Value in Health 17(7): A401-A402, 2014

The safety profile of dalfampridine extended release in multiple sclerosis clinical trials. Clinical Therapeutics 34(5): 1056-1069, 2012

Dalfampridine sustained-release for symptomatic improvement of walking speed in patients with multiple sclerosis. Core Evidence 5: 107-112, 2010

Treatment of walking impairment in multiple sclerosis with dalfampridine. Therapeutic Advances in Neurological Disorders 4(2): 99-109, 2011

Dalfampridine extended release: in multiple sclerosis. Cns Drugs 24(10): 883-891, 2010

PND50 Estimation of the Effect of Dalfampridine Extended Release on Health Utility in Patients With Multiple Sclerosis Using Two Equations for Mapping the MSWS-12 to the EQ-5D. Value in Health 15(7): A554-A555, 2012

Pharmacokinetics of dalfampridine extended release 7.5-mg tablets in healthy subjects and individuals with mild and moderate renal impairment: an open-label study. Journal of Clinical Pharmacology 54(1): 53-60, 2014

Patient perspectives and experience with dalfampridine treatment in multiple sclerosis-related walking impairment: the step together program. Patient 8(3): 283-291, 2016